Nurevo home
Menu

Pre-seed. Working prototype of the data pipeline; preparing clinical validation.

Cognitive screening, in a conversation.

Nurevo builds AI cognitive screening that turns a short, natural conversation into an explainable risk score for cognitive decline, helping clinicians decide who needs specialist assessment first.

In plain terms, Nurevo is building this screening for dementia.

How it works Talk to us

Four signal streams

  • Speech timing and voice

    Pauses, rate, rhythm and fluency. These parts of speech carry across languages.

  • Language

    Vocabulary, structure and coherence.

  • Facial movement

    Movement of the face during the conversation.

  • Background information

    Age, education and other context.

How it works

Three steps, from a short conversation to an explainable risk score.

How it works

  1. 01

    A conversation

    A short guided conversation on a phone or laptop. It is low-burden, and it is designed to feel like a conversation rather than a test.

  2. 02

    Four streams

    Speech timing and voice, language, facial movement, and background information are analysed together.

  3. 03

    A risk score

    A cross-modal transformer combines the streams into one explainable risk score and shows which signals contributed most.

Why this approach

Explainable by design

  • Multimodal

    Multimodal rather than single-signal. Speech, language, facial movement and background information are analysed together.

  • Multilingual

    Built for multilingual populations from the start.

  • Explainable

    Explainable by design. The risk score shows which signals contributed most.

Illustrative example. These marks are not a result. Illustrative design concept, not a product screenshot.

Dementia

Specialist capacity is limited, so many people reach memory services late. Existing screening is slow, feels like a test, and was largely designed around one language and culture. The figures below are the published picture worldwide and in the UK.

Worldwide

  • 57 million 1

    people were living with dementia worldwide in 2021

  • Nearly 10 million 1

    new cases each year

  • More than 60% 1

    of people living with dementia live in low and middle income countries

In the UK

  • 982,000 2

    people are estimated to be living with dementia in the UK

  • More than a third 2

    of people living with dementia in the UK have not been formally identified

  • 1.4 million 2

    people are expected to be living with dementia in the UK by 2040

Source

  1. 1 World Health Organization. Fact sheet updated 26 October 2026. The worldwide counts are for 2021.
  2. 2 Alzheimer's Society. The three UK figures are taken from this page.

Who it is for

Nurevo is being designed for organisations that need a low-burden way to prioritise who should be seen sooner.

  • 01

    Health systems and memory services

    Nurevo is being designed so health systems and memory services can prioritise referrals.

  • 02

    Primary care

    Nurevo is being designed for primary care, as a low-burden conversation that can offer an early signal before a specialist referral.

  • 03

    Care homes and community organisations

    Nurevo is being designed for care homes and community organisations, where a short conversation on a phone or laptop can be offered in the place where the person already is.

  • 04

    Pharmaceutical companies and research partners

    Nurevo is being designed for pharmaceutical companies and contract research organisations, to support recruitment and stratification for early-stage trials.

  • Investors

    Nurevo is a pre-seed company. The investor brief on the About page sets out the stage, the approach and what happens next.

    Read the investor brief

Talk to us

Nurevo is in development and not yet available for clinical use. We welcome conversations about future pilots and research.

Talk to us